Kratom Drug Test Cups

Kratom is a botanical substance from Mitragyna speciosa, a Southeast Asian tree. Its alkaloids — primarily mitragynine — act on opioid receptors, producing stimulant effects at low doses and sedative effects at higher doses. Kratom is not federally scheduled in the US but is banned in several states and monitored by courts and treatment programs because of dependence, withdrawal, and relapse risk.

No. Standard 5, 10, or 12 panel immunoassays do not include a kratom strip, and kratom does not cross-react with the opiate strip. Detecting kratom requires a dedicated KRA panel targeting mitragynine metabolites. MayFlower includes KRA in its 16 panel cup — see the kratom drug test cups collection.

Kratom metabolites are typically detectable in urine for about 3–7 days after use, with longer windows possible for heavy daily users because mitragynine is fat-soluble and accumulates. Occasional single use clears faster. Programs verifying kratom abstinence usually test at least weekly given this window.

KRA is the panel abbreviation for kratom. A KRA strip is an immunoassay calibrated to mitragynine metabolites in urine. On the MayFlower 16 panel cup, KRA sits alongside fentanyl (FEN), ETG alcohol, and TCA, giving treatment and justice programs coverage of the emerging substances standard panels miss.

Substance-use treatment programs (where kratom use can undermine recovery or interact with MAT medications), drug courts and probation departments in jurisdictions where kratom is prohibited by supervision conditions, pain management clinics, and employers in states where kratom is banned. Testing follows the program’s substance policy — the panel must match what the policy prohibits.

Kratom is legal at the federal level in the United States but regulated or banned in a number of states and municipalities, and the FDA has warned against its use due to opioid-like effects and contamination risks. Legality does not determine testability: private programs may prohibit and test for kratom regardless of local retail availability.

Kratom itself is not known to trigger standard opiate or other common panel strips at typical cutoffs. As with all immunoassay screens, unexpected results should be confirmed — kratom-specific confirmation is performed by LC-MS/MS measuring mitragynine and 7-hydroxymitragynine.

The KRA strip reads like every other strip: two lines (C and T) is negative, one line at C only is a preliminary positive, and no control line is invalid. Read at 5 minutes after verifying specimen temperature (90–100 °F). Document the KRA result per analyte along with the other 15 strips.

Clients in recovery sometimes substitute kratom believing it is a safe or undetectable alternative, which can sustain opioid-receptor dependence and complicate MAT. Adding KRA to the panel closes an increasingly common blind spot; programs typically pair it with fentanyl and ETG screening in the 16 panel configuration.

Kratom-inclusive cups are sold by the case with volume-tiered pricing, free shipping on 100+ cups, and same-day dispatch. The MayFlower 16 panel configuration is the kratom-inclusive option — see the wholesale drug test cups collection for case quantities.